

BRAWN

BRAWN BIOTECH LIMITED

(Formarly Known as Brawn Pharmaceuticals Limited) Regd Office: C-64, Lajpat Nagar-1, New Delhi 110024



Standlone Audited Statement of Assets & Liabilities

(Rs. in Lakhs)

	Particulars	As at 31/03/2015	As at 31/03/2014
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share Capital	300.03	300.03
	(b) Reserves and Surplus	193.71	167.95
	Sub-Total - Shareholders' funds	493.74	467.98
2	Non-current liabilities		107100
	(a) Long Term Borrowings		
	(b) Deferred Tax Liabilities (net)	0.26	
	(c) Long Term Provisions	7.18	6.83
	Sub-Total - Non-current liabilities	7.44	6.83
3	Current liabilities		
	(a) Short Term Borrowings	10.99	0.61
	(b) Trade Payables	679.88	677.74
	(c) Other Current Liabilities	131.30	159.67
	(d) Short Term Provisions	76.97	56.88
	Sub-Total - Current liabilities	899.13	894.91
	TOTAL - EQUITY AND LIABILITIES ASSETS	1,400.32	1,369.71
3	ASSETS		
1	Non-current assets		
	(a) Fixed assets	18.92	7.29
	(b) Non-Current Investments	3.00	3.00
	(c) Deferred Tax Assets (net)		1.12
	(d) Long Term Loans and Advances	18.27	30.09
	(e) Other non Current Assets	268.16	268.16
	Sub-Total - Non-current assets	308.35	309.67
2	Current assets		
	(a) Inventories	102.78	171.09
	(b) Trade Receivables	921.51	836.46
	(c) Cash and Cash Equivalents	24.98	18.83
	(d) Short Term Loans and Advances	42.70	33,68
	(e) Other Current Assets	-	7 -
	Sub-Total - Current assets	1,091.97	1,060.05
	TOTAL - ASSETS	1,400.32	1,369.71

Notes:

- 1 The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at its Meeting held on 29.05.2015 and have been audited by the Statutory Auditors of the Company. The figures of the last quarter are the balancing figures between the audited figures in respect of the full financial year and the publised year to date figures upto the third quarter of the current Financial Year.
- 2 Figures of the previous periods have been regrouped and/or rearranged wherever necessary, to confirm to the current period's classification.
- Pursuant to the requirement of the Schedule II of the Companies Act, 2013, the Company has revised the depreciation rates w.e.f. 01.04.2014, as prescribed under the said act. Therefore the Company has adjusted the net residual value aggregating to Rs.2.67 Lac from retained earning and the depreciation for March 2015 quarter and year 2014-15 is higher by Rs.0.61 Lac.

For and on behalf of Board For Brawn Biotech Limited

Trilok Singh

Director better life

Place: New Delhi Date: 29.05.2015

BRAWN BIOTECH LTD.

(Formerly Known as Brawn Pharmaceuticals Ltd.)

REGD. OFFICE: C-64, LAJPAT NAGAR-1, NEW DELHI-110024 TEL,:91-11-29815331,29815264 FAX: 29810424

CORPORATE OFFICE: OLD DELHI STOCK EXCHANGE BUILDING, 4/4B, ASAF ALI ROAD.

NEW DELHI-110002(INDIA) TEL,: 011-32911528, 32911529 FAX: 011-23275208 Website : www.brawnlabs.com



BRAWN BIOTECH LIMITED

(Formarly Known as Brawn Pharmaceuticals Limited) Regd Office: C-64, Lajpat Nagar-1, New Delhi 110024

Statement of Standlone Audited Financial Results for the quarter & year ended 31st March, 2015



	Particulars.	3 months ended 31/03/2015	Preceding 3 months ended 31/12/2014	Corresponding 3 months ended 31/03/2014 in the previous year	Year to date figures for current period ended 31/03/2015	(Rs. in Lakhs) Previous Year ended 31/03/201
		Unaudited	Unaudited	Unaudited	Audited	Audited
1	Income from operations					Addited
	Net sales/ income from operations (Net of excise duty)	776.51	1,147.67	945.09	3,798.08	3,670.4
	Other operating Income	18.30	18.53	30.01	66.56	106.8
	Total income from operations (net)	794.81	1,166.20	975.10	3,864,64	3,777.2
2	Expenses			-	0,004,04	3,111.2
	(a) Cost of materials consumed	2	- 1			
	(b) Purchases of stock-in-trade	686.78	1,048.47	579 93	3,332.58	2.830.5
	(c) Changes in inventories of finished goods, work-in- progress and stock-in- trade	1.15	(6.94)	(32.00)	68.31	(11.2
	(d) Employee benefits expense	1437361	63,500	(*************************************	55.51	(11:2)
	(e) Depreciation and amortisation	44.42	38.69	59.76	151.82	283.35
	expenses	0.25	0.81	0.47	2.62	1.47
	(f) Other expenses	39.30	70.16	347.62	256.20	
	Total expenses	771.91	1,151.19	955.78	3,811,54	629.77
3	Profit / (Loss) from operation before other income, finance costs		1,101.10	333.76	3,811.54	3,733,90
4	and exceptional items (1-2) Other income	22.91	15.01	19.33	53.11	43.34
5	The state of the s	3.60	3 8 5	2.45	5.18	71.24
•	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3±4))	26,50	3233	And the second		7.816.7
6	Finance Cost	9.63	15.01	21.78	58.28	114.58
7	Profit / (Loss) from ordinary activities after finance costs but	2.03	0.21	11.12	10.45	14.20
	before exceptional items (5±6)	16.88	14.80	10.66	47.84	100.20
8	Exceptional items		3-6	36.23	47.04	100.38
9	Profit / (Loss) from ordinary activities before tax (7±8)	16.88	14.80	(25.57)	47.84	77.63 22.75
0	Tax expense	-	6.40	(4.39)	19.41	8.30
1	Net Profit / (Loss) from ordinary activities after tax (9 ± 10)	16.88	8.40	(21.18)	28.43	14.45
2	Extraordinary items (net of tax expense)	-		(22.20)	20.43	14.45
3	Net Profit / (Loss) for the period (11±12)	16.88	8.40	(21.18)	28.43	14.45
4	Paid-up equity share capital	300.03	300.03	300.03	300.03	14.45
	(Face Value of the Share shall be indicated)	Control Control		300.03	300.03	300.03
5	Reserve excluding Revaluation Reserves as per balance sheet of					
5 i	previous accounting year Earnings per share (before extraordinary items) (not	193.71	187.21	165.70	193.71	165.70
21	annualised): in Rs.	0.27			10003111	
	(a) Basic		0.28	(0.71)	0.99	0.70
	(b) Diluted	0.27	0.28	(0.71)	0.99	0.39
6	Earnings per share (after extraordinary items) (not annualised): in Rs.		1577E	(5.71)	0.99	0.39
	in Rs.	0.27	(2/2)24	100000	0.99	0.39
	(b) Diluted	0.27	0.28	(0.71)		
_		0.27	0.28	(0.71)	0.99	0.39

Samonths ended 31/03/2015 3 months ended 31/03/2014 in the 1/03/2014 3 months ended 31/03/2014 in the 1/03/2015 5 months ended 31/03/2015 1.564,224 1.564,224 1.564,224 1.564,224 1.564,224 1.564,224 1.564,224	_	Information	for the quarter & year	ended 31st March,	2015		
- Number of shares		Particulars		3 months ended	3 months ended 31/03/2014 in the	for current period	Year to date figures for the previous year ended 31/03/201
a) Pledged / Encumbered Nil	1	Number of shares Percentage of shareholding	52.14	100000000000000000000000000000000000000		Water State of the Control of the Co	1,564,2 52.
- Number of shares - Percentage of shares (as a % of the total shareholding of promoter and promoter group) - Percentage of shares (as a % of the total share capital of the company) b) Non - encumbered - Number of shares - Percentage of shares (as a % of the total share capital of the Promoter and Promoter group) - Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group) - Percentage of shares (as a % of the total share capital of the company) - Percentage of shares (as a % of the total share capital of the company) - Percentage of shares (as a % of the total share capital of the beginning of the quarter - Nil	7		13/9/7/	1000	57,55011	Nil	Nil
- Percentage of shares (as a % of the total shareholding of promoter and promoter group) - Percentage of shares (as a % of the total share capital of the company) b) Non - encumbered - Number of shares - Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group) - Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group) - Percentage of shares (as a % of the total share capital of the company) Nil Nil Nil Nil Nil Nil Nil Ni		The state of the s	2 390.61			Nil	Nil
of the company) b) Non - encumbered - Number of shares - Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group) - Percentage of shares (as a % of the total share capital of the company) - Percentage of shares (as a % of the total share capital of the company) - Percentage of shares (as a % of the total share capital of the company) - Percentage of shares (as a % of the total share capital of the company) - Particulars - INVESTOR COMPLAINTS - Pending at the beginning of the quarter - Received during the quarter - Disposed of during the quarter - Nil - Remaining unresolved at the end of the quarter - Nil - Remaining unresolved at the end of the quarter		of promoter and promoter group)		507	689	0.0000	700
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group) - Percentage of shares (as a % of the total share capital of the company) - Percentage of shares (as a % of the total share capital of the company) - Particulars INVESTOR COMPLAINTS Pending at the beginning of the quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter		 Percentage of shares (as a % of the total share capital of the company) 					West
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group) - Percentage of shares (as a % of the total share capital of the company) - Percentage of shares (as a % of the total share capital of the company) - Particulars INVESTOR COMPLAINTS - Pending at the beginning of the quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter Remaining unresolved at the end of the quarter			1 436 076	1 426 076	1 436 036	97999 500	
INVESTOR COMPLAINTS Pending at the beginning of the quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter Nil Remaining unresolved at the end of the quarter		of the Promoter and Promoter group)		NEAE STATE	PYA-2000 (1970)	0.000	1,436,07 100.0
INVESTOR COMPLAINTS Pending at the beginning of the quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter Nil		of the company)	47.86	47.86	47.86	47.86	47.8
INVESTOR COMPLAINTS Pending at the beginning of the quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter Nil		Particulars					- Annual Control of the Control of t
Pending at the beginning of the quarter Received during the quarter Disposed of during the quarter Nil Remaining unresolved at the end of the quarter Nil	-	INVESTOR COMPLAINTS					
Disposed of during the quarter Remaining unresolved at the end of the quarter Nil							
Remaining unresolved at the end of the quarter Nil							
S S S S S S S S S S S S S S S S S S S							
		Remaining unresolved at the end of the quarter					



...for better life

BRAWN BIOTECH LTD.

(Formerly Known as Brawn Pharmaceuticals Ltd.)

REGD. OFFICE: C-64, LAJPAT NAGAR-1, NEW DELHI-110024 TEL,:91-11-29815331,29815264 FAX: 29810424 CORPORATE OFFICE: OLD DELHI STOCK EXCHANGE BUILDING, 4/4B, ASAF ALI ROAD,

NEW DELHI-110002(INDIA) TEL,: 011-32911528, 32911529 FAX: 011-23275208 Website : www.brawnlabs.com